Investor Alert

Feb. 25, 2019, 3:11 a.m. EST

AstraZeneca: Positive results from Brilinta trial

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Adria Calatayud

AstraZeneca PLC (AZN.LN) said Monday that its heart drug Brilinta met primary endpoint at a phase 3 clinical trial.

The drug, taken in conjunction with aspirin, showed a statistically significant reduction in major adverse cardiovascular events compared to aspirin alone, the FTSE 100 pharmaceutical company said.

The trial was conducted in more than 19,000 patients with coronary artery disease and type-2 diabetes with no prior heart attack or stroke, AstraZeneca said.

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.